BACKGROUND: Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free and overall survival among women with operable lymph-node-positive breast cancer. The effectiveness of concurrent versus sequential regimens is not known. METHODS: We randomly assigned 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (sequential ACT); four cycles of doxorubicin and docetaxel (doxorubicin-docetaxel); or four cycles of doxorubicin, cyclophosphamide, and docetaxel (concurrent ACT). The primary aims were to examine whether concurrent ACT was more effective than sequential ACT and whether the doxorubicin-docetaxel regimen would be as effective as the concurrent-ACT regimen. The secondary aims were to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women. RESULTS: At a median follow-up of 73 months, overall survival was improved in the sequential-ACT group (8-year overall survival, 83%) as compared with the doxorubicin-docetaxel group (overall survival, 79%; hazard ratio for death, 0.83; P=0.03) and the concurrent-ACT group (overall survival, 79%; hazard ratio, 0.86; P=0.09). Disease-free survival was improved in the sequential-ACT group (8-year disease-free survival, 74%) as compared with the doxorubicin-docetaxel group (disease-free survival, 69%; hazard ratio for recurrence, a second malignant condition, or death, 0.80; P=0.001) and the concurrent-ACT group (disease-free survival, 69%; hazard ratio, 0.83; P=0.01). The doxorubicin-docetaxel regimen showed noninferiority to the concurrent-ACT regimen for overall survival (hazard ratio, 0.96; 95% confidence interval, 0.82 to 1.14). Overall survival was improved in patients with amenorrhea for 6 months or more across all treatment groups, independently of estrogen-receptor status. CONCLUSIONS: Sequential ACT improved disease-free survival as compared with doxorubicin-docetaxel or concurrent ACT, and it improved overall survival as compared with doxorubicin-docetaxel. Amenorrhea was associated with improved survival regardless of the treatment and estrogen-receptor status. (ClinicalTrials.gov number, NCT00003782.) 2010 Massachusetts Medical Society
BACKGROUND: Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free and overall survival among women with operable lymph-node-positive breast cancer. The effectiveness of concurrent versus sequential regimens is not known. METHODS: We randomly assigned 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (sequential ACT); four cycles of doxorubicin and docetaxel (doxorubicin-docetaxel); or four cycles of doxorubicin, cyclophosphamide, and docetaxel (concurrent ACT). The primary aims were to examine whether concurrent ACT was more effective than sequential ACT and whether the doxorubicin-docetaxel regimen would be as effective as the concurrent-ACT regimen. The secondary aims were to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women. RESULTS: At a median follow-up of 73 months, overall survival was improved in the sequential-ACT group (8-year overall survival, 83%) as compared with the doxorubicin-docetaxel group (overall survival, 79%; hazard ratio for death, 0.83; P=0.03) and the concurrent-ACT group (overall survival, 79%; hazard ratio, 0.86; P=0.09). Disease-free survival was improved in the sequential-ACT group (8-year disease-free survival, 74%) as compared with the doxorubicin-docetaxel group (disease-free survival, 69%; hazard ratio for recurrence, a second malignant condition, or death, 0.80; P=0.001) and the concurrent-ACT group (disease-free survival, 69%; hazard ratio, 0.83; P=0.01). The doxorubicin-docetaxel regimen showed noninferiority to the concurrent-ACT regimen for overall survival (hazard ratio, 0.96; 95% confidence interval, 0.82 to 1.14). Overall survival was improved in patients with amenorrhea for 6 months or more across all treatment groups, independently of estrogen-receptor status. CONCLUSIONS: Sequential ACT improved disease-free survival as compared with doxorubicin-docetaxel or concurrent ACT, and it improved overall survival as compared with doxorubicin-docetaxel. Amenorrhea was associated with improved survival regardless of the treatment and estrogen-receptor status. (ClinicalTrials.gov number, NCT00003782.) 2010 Massachusetts Medical Society
Authors: D R Budman; D A Berry; C T Cirrincione; I C Henderson; W C Wood; R B Weiss; C R Ferree; H B Muss; M R Green; L Norton; E Frei Journal: J Natl Cancer Inst Date: 1998-08-19 Impact factor: 13.506
Authors: Nancy E Davidson; Anne M O'Neill; Allen M Vukov; C Kent Osborne; Silvana Martino; Douglas R White; Martin D Abeloff Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Sandra M Swain; Stephanie R Land; Marcie W Ritter; Joseph P Costantino; Reena S Cecchini; Eleftherios P Mamounas; Norman Wolmark; Patricia A Ganz Journal: Breast Cancer Res Treat Date: 2008-02-27 Impact factor: 4.872
Authors: I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Jean-Marc Nabholtz; Carla Falkson; Daniel Campos; Janos Szanto; Miguel Martin; Stephen Chan; Tadeuz Pienkowski; Jerzy Zaluski; Tamas Pinter; Maciej Krzakowski; Daniel Vorobiof; Robert Leonard; Ian Kennedy; Nacer Azli; Michael Murawsky; Alessandro Riva; Pierre Pouillart Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Hanna Bandos; Joy Melnikow; Donna R Rivera; Sandra M Swain; Keren Sturtz; Louis Fehrenbacher; James L Wade; Adam M Brufsky; Thomas B Julian; Richard G Margolese; Edward C McCarron; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Kathryn J Ruddy; Anne O'Neill; Kathy D Miller; Bryan P Schneider; Emily Baker; Joseph A Sparano; Chau Dang; Donald W Northfelt; George W Sledge; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2014-03-02 Impact factor: 4.872
Authors: Jieqiong Liu; Wen Jiang; Kai Mao; Yi An; Fengxi Su; Betty Y S Kim; Qiang Liu; Lisa K Jacobs Journal: Breast Cancer Res Treat Date: 2015-03-13 Impact factor: 4.872